Literature DB >> 22581948

Pruritus in HIV-infected patients in the era of combination antiretroviral therapy: a study of its prevalence and causes.

M Blanes1, I Belinchón, J Portilla, I Betlloch, S Reus, J Sánchez-Payá.   

Abstract

Pruritus is a common symptom in HIV-infected patients. However, there is a lack of studies examining this symptom. We investigated the prevalence of pruritus and its causes in this population by offering the possibility of participating in a skin health programme to all HIV-infected patients who attended our service in Alicante, Spain. Those who accepted (n = 303) underwent an interview and a detailed physical examination by specialists from the Dermatology Department. Between May 2003 and October 2003, 94 patients (31%) reported pruritus: xerosis, seborrhoeic eczema and interdigital tinea pedis were the most frequent dermatological entities responsible for this symptom. Patients with pruritus had higher viral loads (P = 0.006). We conclude that pruritus is still a frequent symptom in HIV-infected patients. To the best of our knowledge this is the first prevalence study of pruritus in an HIV population in the combination antiretroviral therapy (cART) era.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22581948     DOI: 10.1258/ijsa.2009.009189

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  3 in total

1.  Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis.

Authors:  Saadet Inan; Alvaro Torres-Huerta; Liselotte E Jensen; Nae J Dun; Alan Cowan
Journal:  Eur J Pharmacol       Date:  2019-09-27       Impact factor: 4.432

Review 2.  Itch: Epidemiology, clinical presentation, and diagnostic workup.

Authors:  Youkyung S Roh; Justin Choi; Nishadh Sutaria; Shawn G Kwatra
Journal:  J Am Acad Dermatol       Date:  2021-08-21       Impact factor: 11.527

3.  Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic.

Authors:  Saadet Inan; Nae J Dun; Alan Cowan
Journal:  Molecules       Date:  2021-09-11       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.